Knight Therapeutics (KHTRF) 5.5028 $KHTRF Knight Lends a

New Post Public Reply Private Reply Replies (0) Message Board

Jul 12, 2015 at 3:55 AM

Knight Therapeutics (KHTRF) 5.5028 $KHTRF

Knight Lends a Hand to a New Debt Fund
Marketwired - Thu Jul 09, 4:01PM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today that it has invested in the Bloom Burton Healthcare Lending Trust (the "Trust"

managed by Stratigis Capital Advisors Inc. Knight subscribed for $500,000 Trust units as part of a $15.9 million private placement. The Trust will use the proceeds to invest in debt and debt-like securities of emerging commercial-stage public and private Canadian healthcare companies that have been overlooked by traditional lenders.
GUD.TO: 7.35 (+0.37)

Medicure Announces Grant Of Options
PR Newswire - Tue Jul 07, 5:08PM CDT
Medicure Inc. (the "Company"

(TSXV:MPH, OTCQB:MCUJF) announces today that its Board of Directors has approved the grant of 240,000 options to Knight Therapeutics Inc. ("Knight"

pursuant to the Company's Stock Option Plan and to the Company's advisory services agreement with Knight as announced April 14, 2014. The options are set to expire on the fifth anniversary of the date of grant and were issued at an exercise price of $2.50 per share. The options are subject to the approval of the TSX Venture Exchange.
MPH.VN: 2.370 (+0.010)

Knight Amplifies Its Innovative Product Sourcing Strategy
Marketwired - Tue Jul 07, 7:03AM CDT
Knight Therapeutics Inc. (TSX: GUD), through one of its wholly-owned subsidiaries, ("Knight"

announced today that it has expanded its innovative pharmaceutical product sourcing strategy by entering into an agreement with TVM Capital Life Science to invest USD$1.6 million into TVM Life Sciences Venture VII ("TVM Fund"

, a fund dedicated to investments in early-stage molecules from pharmaceutical or biotechnology companies as well as technology platforms.
GUD.TO: 7.35 (+0.37)

Knight Finding NEMO: The Sequel
Marketwired - Thu Jul 02, 7:00AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today that it has entered into an agreement with Sectoral Asset Management Inc. ("Sectoral"

to reinvest US$10 million into its New Emerging Medical Opportunities Fund III, Ltd. ("NEMO III"

life science fund.
GUD.TO: 7.35 (+0.37)

Synergy Strips Corp Does Another Acquisition With the Purchase of U.S. Rights for Neuragen(R)
Marketwired - Wed Jul 01, 5:47PM CDT
Synergy Strips Corp (OTCQB: SNYR) a consumer health care company, today announced through its wholly owned subsidiary Neuragen Corp the purchase from Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company"

, a leading Canadian specialty pharmaceutical company the U.S. rights related to Neuragen(R), an innovative OTC product that helps relieve pain caused by diabetic nerve damage. Knight retains Canadian rights and ex-U.S. global rights to Neuragen(R).
GUD.TO: 7.35 (+0.37)

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF)
Business Wire - Wed Jul 01, 3:30PM CDT
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen that combines Gilead's emtricitabine 200 mg and tenofovir alafenamide (TAF) 25 mg with rilpivirine 25 mg (R/F/TAF) from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older. The data submitted in the NDA support the use of R/F/TAF among patients who are HIV treatment-naive or who are virologically suppressed and want to replace their current antiretroviral treatment regimen.
JNJ: 99.53 (+1.13), GILD: 113.74 (+0.38)

Knight Extends Secured Loan
Marketwired - Fri Jun 26, 5:31PM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company"

, a leading Canadian specialty pharmaceutical company, announced today that it has extended a secured loan of $800,000 to Extenway Solutions Inc. (TSX: EY) ("Extenway"

, an innovative provider of technology solutions for the healthcare industry.
EY.VN: 0.035 (unch), GUD.TO: 7.35 (+0.37)

Knight Creates Synergy With Sale of Neuragen(R) U.S.
Marketwired - Fri Jun 26, 5:31PM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company"

, a leading Canadian specialty pharmaceutical company, announced today that it has entered into a sale agreement with Synergy Strips Corp (OTCQB: SNYR) ("Synergy"

related to the U.S. rights to Neuragen(R), an innovative OTC product that helps relieve pain caused by diabetic nerve damage. Knight retains Canadian rights and ex-U.S. global rights to Neuragen(R).
GUD.TO: 7.35 (+0.37)

Extenway Completes Equipment Financing and Concurrent Private Placement of Convertible Debentures for $1.6-Million
CNW Group - Fri Jun 26, 5:30PM CDT
Extenway Solutions Inc. ("Extenway"

(TSXV: EY) is pleased to announce the closing, as of June 26, 2015 (the "Closing Date"

, of a secured equipment loan from Knight Therapeutics Inc. ("Knight"

to Extenway in the amount of $800,000 (the "Equipment Loan"

and a concurrent private placement of secured convertible debentures of Extenway (the "Debentures"

in the aggregate principal amount of $800,000 (the "Offering"

, for combined gross proceeds to Extenway of $1,600,000.
EY.VN: 0.035 (unch)

Chivalrous Knight Does Pro Bono
Marketwired - Fri Jun 26, 8:01AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company"

, a leading Canadian specialty pharmaceutical company, announced today that it has (1) extended a secured loan of US$15 million to Pro Bono Bio PLC ("Pro Bono Bio"

, the world's leading healthcare nanotechnology company, and (2) entered into an exclusive distribution agreement with Pro Bono Bio to commercialize its wide range of nanotechnology products, medical devices and drug delivery technologies in select territories.
GUD.TO: 7.35 (+0.37)

Finding NEMO Yields Financial Return For Knight
Marketwired - Mon Jun 08, 7:03AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company"

, a leading Canadian specialty pharmaceutical company, announced today that it has received a distribution of US$13.6 million related to its investment in Sectoral Asset Management Inc.'s ("Sectoral"

New Emerging Medical Opportunities Funds II, Ltd. ("NEMO II"

as part of a partial distribution of the fund.
GUD.TO: 7.35 (+0.37)

Knight Secures Canadian Products in Two Separate Transactions
Marketwired - Thu Jun 04, 5:00PM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company"

, a leading Canadian specialty pharmaceutical company, announced the closing of two product transactions.
GUD.TO: 7.35 (+0.37)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TIOmarkets App Unveils Enhanced Trading Features

Trading on the Go Takes a Leap Forward Pretty slick development from TIOmarkets, if I do say so myself. They've rolled out a major expansion of their mobile trading app, now packing some hefty features like Depth of Market and more granular order controls right from those little devices in our pockets. Quite the leap if you're one of those folks who can't keep your eyes...

DAR Logs Massive 587,000 Service Hours Nationwide

A Month of Patriotism and Service You've got to hand it to the Daughters of the American Revolution (DAR)—when they commit, they go all in. This year, they turned their usual Day of Service into a full-blown Month of Service, packing in over 587,000 hours of volunteering nationwide. From historic spots to food pantries, DAR members showed up, and honestly, it's the kind...

Bechtel's $1M Push for Wyoming's Skilled Trades Future

Wyoming's Bid for Skilled Trades Revolution You’d think with all the talk about tech and white-collar jobs, we’ve forgotten the backbone that keeps the world ticking—skilled trades. Turns out, Bechtel hasn’t. The company just tossed a cool million at Wyoming's Laramie County Community College and Western Wyoming College. What’s that doing? It's jumpstarting...

Ashling's New Feat: Microsoft Recognition in AI

Microsoft's Stamp of Approval for Ashling Ah, recognition—it's not just for egos. When Ashling, an AI consultancy heavyweight, gets a nod from Microsoft, it's worth more than a footnote in the company newsletter. This isn't some participation trophy. Nope, it's a badge saying they know their Data & AI, and Digital & App Innovation inside out. On October 29, 2026,...

Newmark's Q3 2026 Financials: Revenue Surges to $3.7B

Breaking Down Newmark's Latest Numbers Ah, Newmark—stepping up again with their quarterly results, and boy, it was nothing short of a spectacle. They just rolled out their third-quarter financials for 2026, and numbers don't lie; they're strutting with $3.7 billion in revenue over the past twelve months. Now, if that doesn't make the investors grin from ear to ear, I...

Pencil Reinvention Aims to Reduce Classroom Waste

Sharpen Those Ideas: Reinventing the Humble Pencil Every classroom has 'em: pencils chewed up faster than a kid chomping through bubblegum. This ain't new. But dig this—a Chicago teacher's coming in hot with a tweak to extend pencil life. How? By addressing the ol' crumbly eraser issue. You know, the kind that vanishes into thin air right when you need it most. So,...

Meitu Sees Soaring Subscriber Growth Amid AI Focus

Subscriber Growth Hits a Record High Well, here's a headline to chew on—Meitu, Inc. is boasting a whopping 19.83 million paying subscribers, setting a new milestone. That's 1.39 million new users this quarter alone, the most significant uptick they've seen in four cycles. Not that I'm surprised; when you've got a product mix like theirs that's riding high on the wave of...

Bandwidth Welcomes Chip Schroeder: Key Board Makeover

Turning the Page at Bandwidth Bandwidth Inc. (NASDAQ:BAND) just shook up its executive roster by bringing in a heavy hitter. Chip Schroeder's landing on the board is a bold move from a strategic player in the cloud communications space. This guy's not your average board member; he's a veteran navigator through stormy market waters, and at Bandwidth, it seems he'll be...

Markel's Reinsurance Shift with $4.8B Deal: Strategic Move?

Weaving Through Complex Insurance Terrain When Markel Insurance pulls a move on the chessboard that involves $4.8 billion in subject reserves, we better pay attention. The insurance bigwig has inked a reinsurance deal with Enstar. This plan, they say, will help them focus more on their specialty insurance game while tidying up the loose ends in their global reinsurance...

Wabi's $1.25B Valuation: A New Era for AI?

A Major Milestone for Wabi Well, here we go—Wabi, the brainchild of Eugenia Kuyda, is stirring the pot with a massive $55 million funding round, pulling its valuation up to a hefty $1.25 billion. If you're raising eyebrows at that price tag, you’re not alone. It's a big number riding on an even bigger idea: that AI isn't just for solitary chats anymore, but for...